OncoMatch/Clinical Trials/NCT06750094
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Is NCT06750094 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for colorectal neoplasms.
Treatment: Amivantamab · Cetuximab · Bevacizumab · 5-fluorouracil · Leucovorin calcium/Levoleucovorin · Irinotecan — The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: KRAS G12 wild-type
KRAS G12 wild type status by local and/or central next-generation sequencing (NGS) testing
Required: KRAS G13 wild-type
KRAS G13 wild type status by local and/or central next-generation sequencing (NGS) testing
Required: NRAS G12 wild-type
NRAS G12 wild type status by local and/or central next-generation sequencing (NGS) testing
Required: NRAS G13 wild-type
NRAS G13 wild type status by local and/or central next-generation sequencing (NGS) testing
Required: BRAF V600 wild-type
BRAF V600X (X represents any single amino acid change from the original amino acid) wild type status by local and/or central next-generation sequencing (NGS) testing
Excluded: MSH2 deficiency (dMMR)
Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments
Excluded: MSH6 deficiency (dMMR)
Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments
Excluded: MLH1 deficiency (dMMR)
Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments
Excluded: PMS2 deficiency (dMMR)
Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments
Excluded: MSI high (MSI-H)
Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments
Excluded: HER2 (ERBB2) positive/amplified
Participant with known human epidermal growth factor receptor 2 (HER2)- positive/amplified tumor
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: fluoropyrimidine-based chemotherapy — metastatic
Participant must have received 1 line of systemic therapy (fluoropyrimidine-based and oxaliplatin-based) for metastatic colorectal cancer (mCRC), with documented radiographic disease progression on or after this line of therapy.
Must have received: oxaliplatin-based chemotherapy — metastatic
Participant must have received 1 line of systemic therapy (fluoropyrimidine-based and oxaliplatin-based) for metastatic colorectal cancer (mCRC), with documented radiographic disease progression on or after this line of therapy.
Cannot have received: irinotecan
Has prior exposure to irinotecan
Cannot have received: EGFR-targeted therapy
Has prior exposure to any agents that target epidermal growth factor receptor (EGFR)
Cannot have received: MET inhibitor
Has prior exposure to any agents that target...mesenchymal epithelial transition (MET)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ironwood Cancer and Research Center · Chandler, Arizona
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Arizona Oncology Associates PC NAHOA · Prescott, Arizona
- St. Bernard's Medical Center · Jonesboro, Arkansas
- Highlands Oncology Group · Springdale, Arkansas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify